Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 22, 2013, Pages 6172-6177

  Turlington, Mark ^a,b   Chun, Aspen ^a,b   Tomar, Sakshi ^c   Eggler, Aimee ^c   Grum Tokars, Valerie ^d   Jacobs, Jon ^a,b   Daniels, J Scott ^a,b   Dawson, Eric ^a,b   Saldanha, Adrian ^e   Chase, Peter ^e   Baez Santos, Yahira M ^c   Lindsley, Craig W ^a,b,f   Hodder, Peter ^e   Mesecar, Andrew D ^c   Stauffer, Shaun R ^a,b,f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

3CLpro; Coronavirus; MERS; SARS; Severe acute respiratory syndrome

Indexed keywords

AMIDE; ANTIVIRUS AGENT; ML 188; ML 300; N [BENZO[1,2,3]TRIAZOL 1 YL) N (BENZYL)ACETAMIDO]PHENYL CARBOXAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SCREENING; HYDROGEN BOND; MOLECULAR WEIGHT; SARS CORONAVIRUS; STRUCTURE ACTIVITY RELATION;

CORONAVIRUS; SARS CORONAVIRUS;

3CLPRO; CORONAVIRUS; MERS; SARS; SEVERE ACUTE RESPIRATORY SYNDROME;

ACETAMIDES; ANTIVIRAL AGENTS; HUMANS; MODELS, MOLECULAR; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885949773     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.08.112     Document Type: Article

References (27)

1. K. McIntosh, J.H. Dees, W.B. Becker, A.Z. Kapikian, and R.M. Chanock Proc. Natl. Acad. Sci. U.S.A. 57 1967 933
2. S.H. Myint S.G. Siddell, Human coronovirus infections 1995 Plenum Press New York 389
3. T.G. Ksiazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A.E. Ling, C.D. Humphrey, W.J. Shieh, J. Guarner, C.D. Paddock, P. Rota, B. Fields, J. DeRisi, J.Y. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W.J. Bellini, and L.J. Anderson N. Eng. J. Med. 348 2003 1953
4. J. Ziebuhr Curr. Opin. Microbiol. 7 2004 412
5. K. Pyrc, B. Berkhout, and L. van der Hoek J. Virol. 81 2007 3051
6. B.C. Fielding Future Microbiol. 6 2011 153
7. L.-J. Cui, C. Zhang, T. Zhang, R.-J. Lu, Z.-D. Xie, L.-L. Zhang, C.-Y. Liu, W.-M. Zhou, L. Ruan, X.-J. Ma, and W.-J. Tan Adv. Virol. 2011 6
8. Centers for Disease Control and Prevention: http://www.cdc.gov/ coronavirus/mers/index.html.
9. A.M. Zaki, S. van Boheemen, T.M. Bestebroer, A.D. Osterhaus, and R.A. Fouchier N. Eng. J. Med. 367 2012 1814
10. Y. Debing, D. Jochmans, and J. Neyts Curr. Opin. Virol. 3 2013 217
11. A.K. Ghosh, D. Xi, M.E. Johnson, S.C. Baker, and A.D. Mesecar Ann. Rep. Med. Chem. 41 2006 183
12. R.P. Jain, H.I. Pettersson, J. Zhang, K.D. Aull, P.D. Fortin, C. Huitema, L.D. Eltis, J.C. Parrish, M.N. James, D.S. Wishart, and J.C. Vederas J. Med. Chem. 47 2004 6113
13. A.K. Ghosh, K. Xi, K. Ratia, B.D. Santarsiero, W. Fu, B.H. Harcourt, P.A. Rota, S.C. Baker, M.E. Johnson, and A.D. Mesecar J. Med. Chem. 48 2005 6767
14. S. Yang, S.J. Chen, M.F. Hsu, J.D. Wu, C.T. Tseng, Y.F. Liu, H.C. Chen, C.W. Kuo, C.S. Wu, L.W. Chang, W.C. Chen, S.Y. Liao, T.Y. Chang, H.H. Hung, H.L. Shr, C.Y. Liu, Y.A. Huang, L.Y. Chang, J.C. Hsu, C.J. Peters, A.H. Wang, and M.C. Hsu J. Med. Chem. 49 2006 4971
15. J. Zhang, H.I. Pettersson, C. Huitema, C. Niu, J. Yin, M.N.G. James, L.D. Eltis, and J.C. Vederas J. Med. Chem. 50 2007 1850
16. X. Xue, H. Yu, H. Yang, F. Xue, Z. Wu, W. Shen, J. Li, Z. Zhou, Y. Ding, Q. Zhao, X.C. Zhang, M. Liao, M. Bartlam, and Z. Rao J. Virol. 82 2008 2515
17. K. Akaji, H. Konno, H. Mitsui, K. Teruya, Y. Shimamoto, Y. Hattori, T. Ozaki, M. Kusunoki, and A. Sanjoh J. Med. Chem. 54 2011 7962
18. J.E. Blanchard, N.H. Elowe, C. Huitema, P.D. Fortin, J.D. Cechetto, L.D. Eltis, and E.D. Brown Chem. Biol. 11 2004 1445
19. W.Q. Chen, C.Y. Lu, T.W. Wong, W.H. Ling, Z.N. Lin, Y.T. Hao, Q. Liu, J.Q. Fang, Y. He, F.T. Luo, J. Jing, L. Ling, X. Ma, Y.M. Liu, G.H. Chen, J. Huang, Y.S. Jiang, W.Q. Jiang, H.Q. Zou, and G.M. Yan Emerg. Infect. Dis. 11 2005 89
20. C.Y. Wu, K.Y. King, C.J. Kuo, J.M. Fang, Y.T. Wu, M.Y. Ho, C.L. Liao, J.J. Shie, P.H. Liang, and C.H. Wong Chem. Biol. 13 2006 261
21. A.K. Ghosh, G. Gong, V. Grum-Tokars, D.C. Mulhearn, S.C. Baker, M. Coughlin, B.S. Prabhakar, K. Sleeman, M.E. Johnson, and A.D. Mesecar Bioorg. Med. Chem. Lett. 18 2008 5684
22. J. Zhang, C. Huitema, C. Niu, J. Yin, M.N.G. James, L.D. Eltis, and J.C. Vederas Bioorg. Chem. 36 2008 229
23. J. Jacobs, V. Grum-Tokars, Y. Zhou, M. Turlington, S.A. Saldanha, P. Chase, A. Eggler, E.S. Dawson, Y.M. Baez-Santos, S. Tomar, A.M. Mielech, S.C. Baker, C.W. Lindsley, P. Hodder, A. Mesecar, and S.R. Stauffer J. Med. Chem. 56 2013 534
24. For an example of 'induced-fit' and discussion on active-site flexibility in the context of inhibitor bound versus unbound SARS 3CLpro using an aza-peptide epoxide see: T.W. Lee, M.M. Cherney, J. Liu, K.E. James, J.C. Powers, L.D. Eltis, and M.N. James J. Mol. Biol. 366 2007 916
25. A.L. Hopkins, C.R. Groom, and A. Alex Drug Discovery Today 9 2004 430
26. R.D. Morrison, A.L. Blobaum, F.W. Byers, T.S. Santomango, T.M. Bridges, D. Stec, K.A. Brewer, R. Sanchez-Ponce, M.M. Corlew, R. Rush, A.S. Felts, J. Manka, B.S. Bates, D.F. Venable, A.L. Rodriguez, C.K. Jones, C.M. Niswender, P.J. Conn, C.W. Lindsley, K.A. Emmitte, and J.S. Daniels Drug Metab. Dispos. 40 2012 1834
27. For information on MLPCN's probe compound ancillary screen see Eurofins LeadProfilingScreen®: www.eurofinspanlabs.com.